Collectively, our results strengthen our hypothesis that in ESCC, MSCs-derived B2M promotes tumor-initiation and invasion via enhancing EMT, resulting in a poor clinical outcomes for the patients. The gene discussed is B2M; the disease is esophageal squamous cell carcinoma.